Michael Loberg, Ph.D., Chairman
Dr. Loberg previously served on the Board of Directors of ArQule, a biopharmaceutical company that was acquired by Merck in January 2020, and was also a member of its Compensation, Nominating and Governance Committee and Science Committee. Dr. Loberg has also held a number of senior management positions at Bristol-Myers Squibb, including President of Bristol-Myers Squibb’s Oncology and Immunology, U.S. Primary Care, Northern Europe, Specialty Pharmaceuticals and Squibb Diagnostics divisions, as well as Director and Vice President, E.R. Squibb & Sons Research and Development. Dr. Loberg previously served on the Board of Directors and as Interim Chief Executive Officer of Inotek Pharmaceuticals and as Chief Executive Officer and a member of the Board of Directors of NitroMed. Dr. Loberg received a B.S. in Chemistry from Trinity College and a Ph.D. in Chemistry from Washington University in St. Louis.

Felix J. Baker, Ph.D.
Dr. Baker is Co-founder and Managing Member of Baker Bros. Advisors LP, a biotechnology-focused investment adviser to fund partnerships whose investors are primarily endowments and foundations. He serves on the Boards of Alexion Pharmaceuticals, Seagen, Kodiak Sciences, and Kiniksa Pharmaceuticals. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school.

M. Kathleen Behrens, Ph.D. 
Dr. Behrens also serves as a member and Chair of the Board of Directors of Sarepta Therapeutics, a medical research and drug development company, and is also Chairperson of its Audit Committee and a member of its Research and Development Committee. She is also a member and Chair of the Board of Directors of MiMedx Group, a wound care company, as well as a member of its Compliance and Ethics Committee. Dr. Behrens served on the Board of Directors of Amylin Pharmaceuticals, a biotechnology company, from June 2009 until its sale to Bristol-Myers Squibb in 2012. From 1983 to 1996, she served as a General Partner and Managing Director at Robertson Stephens & Co., an investment bank focused on technology companies. From 1996 to 2009, Dr. Behrens continued in her capacity as a general partner for selected venture funds for RS Investments, an investment management and research firm, after management led a buyout of RS Investments from Bank of America. While at RS Investments, she served as a Managing Director from 1996 to 2002, and as a consultant from 2003 to 2009. She served as a member of the President’s Council of Advisors on Science and Technology (PCAST) from 2001 to early 2009 and as Chairwoman of its subcommittee on Personalized Medicine. Dr. Behrens also served as a Director of Science, Technology and Economic Policy for the National Research Council and as a Director, President and Chairwoman of the National Venture Capital Association. Dr. Behrens received a B.S. in Biological Sciences and a Ph.D. in Microbiology from the University of California, Davis.

Julie Hambleton, M.D. 
Dr. Hambleton also serves on the Board of Directors at Accent Therapeutics, SpringWorks Therapeutics and at Arch Oncology where she was also Interim Chief Executive Officer. Previously, she was the Chief Medical Officer and Head of Development at IDEAYA Biosciences, an oncology medicine company. Prior to IDEAYA, she was Vice President and Head of U.S. Medical at Bristol-Myers Squibb. She has also served as Executive Vice President and Chief Medical Officer at Five Prime Therapeutics, Vice President of Clinical Development at Clovis Oncology, and held increasing roles of responsibility in BioOncology at Roche/Genentech, most recently as Global Cluster Head and Global Group Medical Director. Dr. Hambleton completed her hematology-oncology training at the University of California, San Francisco, and served on the faculty there from 1993 to 2003. Dr. Hambleton received a B.S. in Nursing from Duke University and an M.D. from Case Western Reserve University School of Medicine. She is board-certified in Hematology and Internal Medicine.

Michael Lee
Mr. Lee is a Co-founder and Portfolio Manager at Redmile Group, LLC, a health care-focused investment firm based in San Francisco and New York. Prior to Redmile, he worked as a biotechnology investor at Steeple Capital, and before that at Welch Capital Partners and Prudential Equity Group. Mike holds a B.S. in Molecular and Cellular Biology from the University of Arizona.

Fred M. Schwarzer
Mr. Schwarzer has served as our Chief Executive Officer and a member of our Board since 2010. Mr. Schwarzer was a Managing Partner of Charter Life Sciences, a venture capital firm specializing in life sciences investments, for approximately 15 years. He also served as Chairperson of Inviragen, the creators of the DENVax dengue vaccine, from the time of its first venture capital financing until its acquisition by Takeda. Mr. Schwarzer previously served as Chief Executive Officer and then Chair of the Board of Directors of Heska Corporation, a biotechnology company. Mr. Schwarzer received a B.A. in Pre-Legal Studies from the University of Michigan and a J.D. from the University of California, Berkeley, School of Law.

William Strohl, Ph.D. 
Dr. Strohl is the Founder and President of BiStro Biotech Consulting, a biotechnology consulting company. Previously, Dr. Strohl served as Vice President and Biologics Fellow at Janssen BioTherapeutics, the therapeutic biologics organization within the Janssen Research & Development division of Johnson & Johnson, and he served as its Vice President and Head from October 2013 to February 2016. Prior to that, Dr. Strohl served as Head of Antibody Discovery at Janssen BioTherapeutics. Dr. Strohl also held various roles at Merck, including leading Natural Products Biology and leading biologics discovery efforts. Previously, he was a Professor in the Department of Microbiology and the Program of Biochemistry at The Ohio State University. Dr. Strohl received a B.S. in Biology from Central Michigan University and a Ph.D. in Microbiology from Louisiana State University.

Christina Teng Topsøe
Ms. Topsøe serves on the Board of Directors of Haldor Topsøe, and Haldor Topsøe Holding, its holding company. Ms. Topsøe was previously a lawyer at Allen & Overy LLP and Simpson Thacher and Bartlett LLP. Ms. Topsøe received an LL.B. from the University of London and an M.B.A. from London Business School and Columbia Business School.

Jakob Haldor Topsøe
Mr. Topsøe is the Vice Chair of Haldor Topsøe and Chairman of the Board of Haldor Topsøe Holding, its holding company. He is also a member of the Boards of Motortramp, a Danish provider of marine transportation services, and Dampskibsselskabet Orients Fond, a Danish charitable foundation. Mr. Topsøe is an Associated Partner at AMBROX Capital, a Danish investment management firm. He was previously Head of Equities at ABN AMRO Bank in Denmark. Mr. Topsøe holds a Graduate Diploma in Business Administration from the Copenhagen Business School.